Ex Parte Ashkenazi - Page 4

                 Appeal 2007-0866                                                                                      
                 Application 09/993,234                                                                                
                        The Examiner makes the following findings of fact:                                             
                 1.  The claimed subject matter receives the benefit of Appellant’s parent                             
                 Application No. 08/710,802, filed September 23, 1996 (Final Rejection 3).                             
                 Accordingly, the earliest effective filing date of the instant invention is                           
                 September 23, 1996.                                                                                   
                 2.  “[A]n isolated nucleic acid encoding a polypeptide comprising amino                               
                 acid residues ‘25-198’ of ‘SEQ ID NO: 6’ as recited in the appealed claim                             
                 34 is anticipated by the isolated nucleic acid encoding amino acids 36-209 of                         
                 SEQ ID NO: 2 of . . . ‘285 . . . [the corresponding provisional application of                        
                 Yu]” (Answer 5-6).3                                                                                   


                                                                                                                      
                 3 There is some ambiguity on this record with regard to the exact sequence,                           
                 identified by “SEQ ID NO”, that is relied upon to establish the Examiner’s                            
                 prima facie case.  Accordingly, we take a moment to clarify the                                       
                 nomenclature regarding Yu and the ‘285 provisional application.  Yu teaches                           
                 two proteins: DR3-VI and DR3.  For DR3-VI, Yu teaches nucleic acid                                    
                 sequence (SEQ ID NO: 1) (Yu, col. 4, l. 67 – col. 5, l. 1) and protein                                
                 sequence (SEQ ID NO: 2) (Yu, col. 4, ll. 56-57).  For DR3, Yu teaches the                             
                 nucleic acid sequence (SEQ ID NO: 3) and protein sequence (SEQ ID NO:                                 
                 4) (Yu, col. 6, ll. 3-12).  As Appellant explains, ‘285 only teaches the                              
                 nucleic acid and protein sequences of DDCR (Br. 5), which Yu teach is the                             
                 former name of DR3-VI (Yu, col. 5, ll. 59-62).  ‘285 teaches that the isolated                        
                 nucleic acid of DDCR (DR3-VI) has a sequence as set forth in SEQ ID NO:                               
                 1 (‘285 10: 14-16), and the DDCR protein has the sequence as set forth in                             
                 SEQ ID NO: 2 (‘285 11: 8-26).  While the Examiner initially refers to SEQ                             
                 ID NO: 3 of Yu (Answer 4), the Examiner clarifies that in reality it is SEQ                           
                 ID NOs: 1 and 2 of ‘285 that serve as the basis for the Examiner’s prima                              
                 facie case.  As Appellant recognizes that ‘285 is the only disclosure that pre-                       
                 dates Appellant’s filing date (Br. 5) and directs attention to the DR3-VI                             
                 sequence in ‘285 (Br. 5-10), we find that the Examiner’s reference to SEQ                             
                 ID NO: 3 in Yu is a harmless error and that Appellant had a fair opportunity                          
                 to address, and in fact did address, the teachings in ‘285.                                           
                                                          4                                                            

Page:  Previous  1  2  3  4  5  6  7  8  9  10  Next

Last modified: September 9, 2013